ANTHEMNSEAnthem Biosciences LimitedHighPositive
Announced Tue, 19 May · 21:09 IST

Anthem Biosciences Limited has informed the Exchange that Board of Directors at its meeting held on May 19, 2026, recommended Final Dividend of Rs. 2 per equity share.

Corporate Actions View source PDF

ANTHEM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-1.3%1-day move
₹780.00
prior close
₹801.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.2+1.0+0.8+0.4-1.3-0.5-2.2-1.3-3.0-3.8+0.0-1.7+1.2
Up moveDown movePending
AI summary

Anthem Biosciences Limited's Board approved audited financial results for FY2026 ending March 31, 2026. Standalone revenue grew to Rs. 2,089.31 million from Rs. 1,840.65 million, while profit after tax increased to Rs. 5,701.64 million from Rs. 5,061.79 million. Annual EPS improved to Rs. 10.15 from Rs. 9.05. The Board recommended a final dividend of Rs. 2 per equity share (100% payout on face value of Rs. 2) for FY2026, subject to shareholder approval at the July 22, 2026 AGM. The record date for dividend is June 26, 2026. Additionally, 14,81,250 equity shares were allotted under the ESOP 2024 scheme, increasing paid-up capital to Rs. 1,12,63,90,202.

Likely market impact

The company declared a 100% dividend payout on face value, signaling strong financial health. However, based on the IPO issue price of Rs. 570, the dividend yield is approximately 0.35%, which does not qualify as a high-yield signal. The growth in revenues and profits alongside the ESOP allotment indicates good operational performance.